REBECCA DAVIS: Open Payments
NPI 1831507078 · BATON ROUGE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,015 in 47 payments from 13 companies in 2025. Trend: 2023 $1,039 · 2024 $944 · 2025 $1,015
Food & beverage: $1,015
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 13 | $263 |
| Vanda Pharmaceuticals Inc. | 8 | $242 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $82 |
| ABBVIE INC. | 4 | $75 |
| AstraZeneca Pharmaceuticals LP | 3 | $64 |
| Lundbeck LLC | 3 | $64 |
| Lilly USA, LLC | 3 | $64 |
| Otsuka America Pharmaceutical, Inc. | 2 | $40 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $34 |
| Exact Sciences Corporation | 2 | $33 |
Products named: FANAPT, REPATHA, OTEZLA, REXULTI, CAPLYTA, BREZTRI, MOUNJARO, VRAYLAR.
Industry payments across LA — which companies pay providers there.
